acquires US drugmaker Assertio in Rs 1,600 crore deal. Zydus Lifesciences acquires Assertio Holdings for $166.4 mn, expanding into US specialty and oncology markets. Zydus will acquire all outstanding shares at $23.50 a share, expected to close in FY27. Assertio has $68.23 mn revenue in 2025, with commercial portfolio anchored by Rolvedon, a long-acting G-CSF used in cancer treatment. This deal strengthens Zydus's position in oncology supportive care. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.